Less than a year after it was spun out of Spanish biotech firm Zeltia, Sylentis is hoping to become a major player in the RNAi drugs field with programs in ophthalmology and digestive disease.
The company, which currently has five full-time employees focused on research and development, is also in the process of establishing a scientific advisory board to help shepherd its lead drug compound — a treatment for glaucoma — through primate testing and into the clinic.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
